login
  Password reminder
Spinal News
Contact the editor Visit Spinal News Twitter feed Visit Spinal News Facebook page
 

Understanding the pathology behind disc degeneration


Friday, 25 May 2012 12:59
Sally Roberts
Sally Roberts


Sally Roberts, Centre for Spinal Studies & ISMA (Keele University), Robert Jones & Agnes Hunt Orthopaedic Hospital, Oswestry, UK, talked to Spinal News International about the current understanding of the pathology behind disc degeneration. She spoke about “Disc biology and tissue engineering” at The Annual Imperial Spine Course (7–9 March 2012, London, UK) and will be speaking about disc degeneration at Spineweek (28 May–1 June 2012, Amsterdam, The Netherlands)


What is the pathology behind disc degeneration?

In disc degeneration, the matrix of the disc can no longer function normally because the extra cellular matrix (ECM) becomes degraded, losing some molecules, particularly proteoglycans and their constituent glycosaminoglycans. This process almost certainly involves the resident cells within the disc. While we know quite a lot about different enzymes and other molecules that can be involved, the exact sequence of events and trigger factors are not always clear. I suspect there may be many different pathways resulting in a similar endpoint. As with so many other things, our genes play a significant part in whether degeneration will happen or not.


What are the ways that cell therapy is being proposed as a treatment for disc regeneration?

It has not just been proposed—it has already been used in patients! For example, autologous cells from herniated discs cultured in vitro and injected back into the disc has been performed for some years in Germany, and mesenchymal stem cells from the patient’s bone marrow have been injected into discs in the USA and Japan.


Meantime, there are many aspects of cell therapy that are being researched, such as: attempting to identify the best cell type to use and whether this should be autologous or allogeneic; whether cells should be from the annulus fibrosus or nucleus pulposus; or whether they should be stem cells and if so from where—bone marrow or adipose tissue or somewhere else?; and should a carrier or scaffold be used?

What questions do we need to answer before we can routinely use cell therapy to treat disc degeneration?


A very important question is “which patients would benefit most from such treatment?” For example, should you select only very degenerate discs to treat? If so, the rest of the spinal structure, nutrient pathways, vascularisation etc. may not be able to support the implanted cells. But then would surgeons be happy to treat, and would patients want to have cells implanted into discs, if the degeneration (or more importantly, the pain) was not too bad?


More recently another big question has been raised and this is about how the cells should be introduced to the disc. I believe most people imagined, until a couple of years ago, that cells could be injected (minimally invasively) into the discs, but there are now several studies indicating that a needle hole, however small, may be very bad news for the disc long term and such a “puncture” can actually contribute to degeneration of the disc.


What role can spinal surgeons play in helping to answer these questions?


They can help researchers by providing clear grouping of (or characterising) patients in terms of diagnoses and phenotyping. They can work with scientists and other researchers in providing:

  • Ideas and hypotheses to test
  • Surgical samples for scientific investigations
  • Being active in collaborative studies


These factors are really important to progressing the field of research in disc degeneration.




Add New Comment

Most popular


New device allows brain to bypass spinal cord and move paralysed limbs
Friday, 27 Jun 2014
For the first time ever, a paralysed man has moved his fingers and hand with his own thoughts after an electronic neural bypass for spinal cord injuries that reconnects the brain directly to muscles, ... New device allows brain to bypass spinal cord and move paralysed limbs

Tantalum porous implant is a good alternative to plate and autograft in ACDF
Friday, 13 Jun 2014
A new study indicates that patients undergoing anterior cervical discectomy and fusion (ACDF) with a tantalum implant have fewer complications and reduced costs at five years compared with patients ... Tantalum porous implant is a good alternative to plate and autograft in ACDF

Electrical nerve stimulation could reduce spasticity in spinal cord injury
Friday, 27 Jun 2014
A new study indicates that transcutaneous electrical nerve stimulation (TENS) plus standardised physical therapy reduces clinical spasticity in patients with a subacute spinal cord injury compared ... Electrical nerve stimulation could reduce spasticity in spinal cord injury

Features


The ASIA impairment scale for spinal injuries may show worsening despite neurological improvement
Thursday, 31 Jul 2014
Ibrahim Gündoğdu and colleagues report in Spinal Cord that the American Spinal Injury Association (ASIA) impairment scale is limited because it could show worsening despite a patient with a spinal ... The ASIA impairment scale for spinal injuries may show worsening despite neurological improvement

Can cognitive behavioural therapy help spinal surgery patients return to work and daily life?
Friday, 11 Jul 2014
Nanna Rolving and colleagues have launched a study to investigate the clinical effectiveness and cost-effectiveness of using a multidisciplinary cognitive behavioural intervention to help patients ... Can cognitive behavioural therapy help spinal surgery patients return to work and daily life?

Profiles


Luiz Pimenta
Thursday, 12 Jun 2014
Luiz Pimenta, immediate past president of the International Society for the Advancement of Spinal S... Luiz Pimenta

Frank Schwab
Thursday, 17 Apr 2014
Frank Schwab (chief of the Spinal Deformity Service, Division of Spine Surgery, New York University,... Frank Schwab

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions